Cingulate Inc Stock Price, News & Analysis

Cingulate Inc. (NASDAQ: CING) announced its Q2 financial results, highlighting a $5 million non-dilutive debt financing and the appointment of Scott Applebaum to its Board of Directors. As of June 30, 2022, Cingulate's cash and equivalents stood at $8.2 million. R&D expenses rose to $2.2 million, while G&A expenses increased to $1.9 million, leading to a net loss of $4 million for the quarter. The company plans to continue development of its ADHD treatment, CTx-1301, with a Phase 3 study expected to commence soon. Positive NDA filing anticipated by late 2023 requires additional capital of $16.5 million.

Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company, announced that its CFO, Lou Van Horn, was honored as a 2022 CFO of the Year by the Kansas City Business Journal. This is the second time Lou has received this accolade, recognizing his financial leadership and expertise. The award ceremony took place on July 22, 2022. Lou, who played a crucial role in Cingulate's IPO in 2021, expressed gratitude for the recognition and highlighted the positive economic outlook for the Kansas City region.

Cingulate Inc. has announced the completion of the formulation study for CTx-2103, a new once-daily treatment for anxiety-related disorders using its proprietary Precision Timed Release™ (PTR™) drug delivery technology. This study, conducted in the UK, aims to improve adherence by reducing the dosing frequency of the active ingredient, buspirone. Results are anticipated in August 2022. CTx-2103 is designed to offer significant advantages over existing medications while addressing a substantial market need, as anxiety disorders affect approximately 31% of U.S. adults at some point in their lives.

Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company, will present a company overview at the Diamond Equity Research 2022 Virtual Emerging Growth Invitational on June 23, 2022, at 1:40 PM EST. Chairman and CEO, Shane J. Schaffer, PharmD, will lead the presentation and follow up with a Q&A session. Investors can register for the event and access live webcasts via the provided links. Cingulate focuses on its proprietary Precision Timed Release™ (PTR™) drug delivery technology for developing next-generation products, initially targeting ADHD.

Cingulate Inc. (NASDAQ: CING) has announced that its Chairman and CEO, Shane J. Schaffer, and scientific advisor, Dr. Ann Childress, will participate in a live event on June 3, 2022, at 8:45 a.m. CST, hosted by Benzinga. The discussion will focus on unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD) and the expansion of Cingulate's Precision Timed Release™ (PTR™) platform into anxiety treatments. This event can be accessed via Benzinga’s YouTube channel and Cingulate's website.

Cingulate Inc. (NASDAQ: CING) announced the completion of enrollment in a clinical study for CTx-2103, a novel buspirone formulation aimed at treating anxiety disorders. This study, initiated in May 2022 with 12 participants, is set to yield results in July 2022. CTx-2103 employs Cingulate's proprietary Precision Timed Release™ (PTR™) technology, enabling once-daily dosing. The formulation could address issues of nonadherence prevalent with current treatments, offering potential for improved patient outcomes in a significant $5.5B U.S. anxiety market.

Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company, will present an overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, from 3:00-3:30 p.m. ET in Miami, FL. The presentation will feature insights from CEO Shane J. Schaffer and CMO Matthew Brams, M.D. Interested investors can access the live webcast and later view a replay on Cingulate’s investor website for 90 days. The company focuses on its proprietary Precision Timed Release™ (PTR™) technology, primarily targeting ADHD treatment while exploring other therapeutic areas like anxiety disorders.

Cingulate Inc. (NASDAQ: CING) announced its financial results for Q1 2022 and dosed the first subject in a human formulation study of CTx-2103 for anxiety. The company aims to provide a single-dose therapeutic solution due to current treatment limitations. CTx-2103 could capture a segment of the U.S. anxiety market, valued over $5.5 billion. Cingulate reported a net loss of $5 million for the quarter and incurred R&D expenses of $2.8 million, reflecting an increase due to clinical activities. Cingulate seeks $21.5 million in additional capital to advance its projects.

Cingulate Inc. (NASDAQ: CING) presented a company overview at NobleCon18, highlighting its proprietary Precision Timed Release™ (PTR™) drug delivery platform. CEO Shane J. Schaffer detailed the company's focus on developing next-generation pharmaceuticals, particularly for Attention Deficit/Hyperactivity Disorder (ADHD). The presentation is available to view on the company’s website and will be archived for 90 days. Cingulate aims to improve treatment outcomes for patients with burdensome dosing regimens, with potential future applications in anxiety disorders.